Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibiofilm efficacy of zwitterionic 2-methacryloloxyethyl phosphorylcholine (MPC) polymer coatings against Vibrio fischeri.

Water research·2026
Same author

Sphingosine-1-phosphate cross-talks to Notch via a S1PR1-Dll4-MPDZ complex to regulate endothelial barrier function.

bioRxiv : the preprint server for biology·2026
Same author

Electrical Stimulation Directs Formation of Perfused Vasculature in Engineered Tissues.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

A 3D In Vitro Model of the Human Hepatobiliary Junction.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Synthetic control of implanted engineered liver tissue growth.

Science advances·2026
Same author

A 3D microfluidic model of exchange between perfused blood and lymphatic microvascular networks.

Lab on a chip·2026

Related Experiment Video

Updated: Jul 28, 2025

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.4K

High throughput screening system for engineered cardiac tissues.

Marshall S Ma1,2, Subramanian Sundaram3, Lihua Lou4

  • 1Mechanical Engineering, Boston University, Boston, MA, United States.

Frontiers in Bioengineering and Biotechnology
|May 30, 2023
PubMed
Summary
This summary is machine-generated.

A new mosaic imaging system enhances drug cardiotoxicity screening by enabling high-throughput, real-time monitoring of contractile forces in 3D engineered cardiac tissues (3D ECTs). This innovation significantly reduces assay time and cost for preclinical drug development.

Keywords:
PDMScardiotoxicity screeningengineered cardiac tissuehigh throughput imaging(HTI)micro manufacturing

More Related Videos

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications
09:50

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications

Published on: August 20, 2021

3.5K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

1.9K

Related Experiment Videos

Last Updated: Jul 28, 2025

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

10.4K
Fibroblast Derived Human Engineered Connective Tissue for Screening Applications
09:50

Fibroblast Derived Human Engineered Connective Tissue for Screening Applications

Published on: August 20, 2021

3.5K
High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

1.9K

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • Drug Discovery

Background:

  • Three dimensional engineered cardiac tissues (3D ECTs) are vital in vitro models for assessing drug cardiotoxicity.
  • Current methods for measuring 3D ECT contractile forces are low-throughput, limiting their use in pharmaceutical development.
  • Existing imaging techniques face tradeoffs between resolution, field of view, and speed, restricting the number of samples analyzed simultaneously.

Purpose of the Study:

  • To develop and validate an innovative mosaic imaging system for high-throughput contractile force sensing of 3D ECTs.
  • To overcome the limitations of conventional imaging in terms of speed, resolution, and field of view.
  • To enable parallel, real-time monitoring of contractile forces in a 96-well plate format.

Main Methods:

  • Design and construction of a novel mosaic imaging system.
  • Seeding of 3D ECTs onto a 96-well plate.
  • Validation of the system through real-time, parallel contractile force monitoring over three weeks.
  • Pilot drug testing using isoproterenol.

Main Results:

  • The mosaic imaging system successfully monitored contractile forces of 3D ECTs in parallel for up to three weeks.
  • The system demonstrated the ability to perform pilot drug testing, showing its practical application.
  • The throughput for contractile force sensing was increased to 96 samples per measurement.

Conclusions:

  • The developed mosaic imaging tool significantly enhances the throughput of preclinical cardiotoxicity assays using 3D ECTs.
  • This approach reduces the cost, time, and labor associated with drug safety testing.
  • The mosaicking strategy offers a generalizable method for scaling up image-based screening in multi-well plate formats.